Biologics and severe asthma in children

Area of Science:

• Pediatric Pulmonology
• Immunology
• Pharmacology

Background:

• Severe asthma presents significant morbidity and mortality, impacting patients, families, and healthcare systems.
• Biologic agents represent a revolutionary advancement in managing severe asthma.
• Evidence for biologics in pediatric populations is growing, demonstrating significant improvements in care.

Approach:

• This review discusses currently approved biologic therapies for severe asthma in school-aged children and adolescents.
• It synthesizes findings from randomized controlled trials evaluating these agents in pediatric populations.
• The focus is on efficacy, safety, and appropriate patient selection.

Key Points:

• Biologics significantly reduce severe asthma exacerbations by 40-70% in pediatric patients.
• Improvements observed include better asthma control, enhanced lung function, reduced oral corticosteroid use, and improved quality of life.
• These therapies demonstrate reassuring safety profiles in children and adolescents.

Conclusions:

• Multiple biologic agents are approved for children (ages 6-11) and adolescents (ages >12), necessitating careful selection.
• Therapy choice should be guided by individual patient asthma phenotype and relevant biomarkers.
• Further pediatric-specific clinical trials are needed to develop evidence-based guidelines for biologic use in this population.